Community Health Network partners with the International Genomics Consortium as a key network tissue source site for National Institutes of Health cancer genome project
Phoenix, AZ, and Indianapolis, IN----Community Health Network announced today that it has agreed to collaborate with the International Genomics Consortium (IGC) in Phoenix to serve as a critical network Tissue Source Site (TSS) to provide cancer tissue samples for analysis in the National Institutes of Health’s (NIH’s) historic project, The Cancer Genome Atlas project (TCGA). Community Health Network will provide cancer tissue samples under uniform and standardized conditions and also collect specific long-term clinical outcome data to facilitate research into the underlying cancer mechanisms.
IGC’s Expression Project for Oncology (expO) has combined its network and mission with TCGA to help create a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.
The overarching goal of TCGA is to improve the ability to diagnose, treat and prevent cancer. TCGA is one of the largest initiatives to date to analyze such a wide array of cancers with so many different genomic analyses, ranging from sequencing to methylation studies.
The genomic blueprints of each cancer will be available on the web for all scientists to have access to for translational discoveries. TCGA plans to analyze 500 tumors from each cancer type studied by the program and will provide the clinically annotated outcome data, along with the complete genomic analysis on the web, free of any intellectual property restrictions.
IGC plans to retain a portion of each sample that it provides to TCGA, if available, to expedite translational discoveries to help patient care, in work separate from TCGA. Additional information on TCGA may be found at http://cancergenome.nih.gov/.
“We look forward to supporting The Cancer Genome Atlas project and other initiatives at IGC through our research efforts here at Community Health Network and continuing not only to provide world class patient care, but also facilitate ground breaking cancer research,” said Jeffrey Mossler, M.D., with Community Health Network.
“We are honored to partner with Community Health Network on this historic NCI initiative to join in the fight against cancer,” said Robert Penny, M.D., Ph.D., IGC’s CEO and principal investigator for both the TSS and Biospecimen Core Resource components of TCGA.
David Mallery, J.D., M.B.A., IGC president, noted that “Together with Community Health Network, we look forward to providing the critical biospecimens and data necessary to facilitate translational research.”
IGC thanks the National Cancer Institute, the National Human Genome Research Institute, Maricopa County, the City of Phoenix, AmeriPath Quest, US Oncology, Science Foundation Arizona, the Flinn Foundation as well as many of the pharmaceutical companies that have provided financial and leadership support to IGC.
About Community Health Network
Ranked among the nation’s most integrated healthcare systems, Community Health Network is Central Indiana’s leader in access to innovative and compassionate healthcare services, where and when patients need them—in hospitals, in convenient health pavilions and doctor’s offices, in the workplace, at schools, in the home and online. As a non-profit health system with multiple sites of care and affiliates throughout Indiana, Community’s full continuum of care integrates hundreds of physicians, acute care and specialty hospitals, surgery centers, physician offices, home care services, walk-in care centers and employer health services. To put the needs and the convenience of patients first, Community pioneers advanced treatments and world-class health information technologies, with a focus on ease of access to exceptional care.
The International Genomics Consortium (IGC) is a non-profit medical research foundation established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining world-class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. IGC serves numerous common, unmet needs including: the standardization of the collection of properly consented tissues of interest, the molecular characterization of these tissues, and standardization in the representation and analysis of these results. IGC participates in the translation of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic, and predictive testing, and their associated new drug and treatment regimens are developed. For more information, visit www.intgen.org.